Magellan Team Discusses 'Mortgage-like' Payments For Ultra-Expensive Gene Therapies | AMCP 2023
When asked for solutions in better managing expensive drug costs, Michelle Booth of Magellan suggests a "mortgage-like" payment that could help make these therapies, which are covered under medical benefits, more accessible and affordable. Because there aren't many gene therapies out there just yet in the market, there hasn't been much pressure in offering discounts through value-based contracts to patients. Though, more discussions on this initiative are happening, Andy Killpack also of Magellan, said in the second-part of a two part AMCP annual meeting video series.
When asked for solutions in better managing expensive drug costs, Michelle Booth, Senior Director of Specialty Clinical Solutions of Magellan suggests a "mortgage-like" payment model that could help make these therapies, which are covered under medical benefits, more accessible and affordable.
"I know there isn't one great mortgage-like payment out there, but we need to realize this needs to be tweaked over time," she said of the suggestion.
Related: Adeno-Associated Virus Gene Therapies in the Pipeline, Barriers to Existing Drugs and Solutions
There would need to be more prevelance on these gene therapy conditons and more drugs to be approved that are expensive to see some action. If the affordability issue continues to be a problem, that's when pivoting toward new options will be necesneces.
Because there aren't many gene therapies out there just yet in the market, there hasn't been much pressure in offering discounts through value-based contracts to patients. Though, more discussions on this initiative are happening, Andy Killpack, director of Specialty Clinical Solutions of Magellan, said.
Specialty Drugs Dominate Pharmaceutical Frontier in 2025
April 15th 2025In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what to expect from the traditional drug pipeline.
Read More
340B Program Is Driving Up Costs and Needs Urgent Reform | AMCP Annual 2025
April 7th 2025At the 2025 AMCP annual meeting in Houston from March 31 to April 3, John M. O'Brien, Pharm.D., MPH, president and CEO of the National Pharmaceutical Council (NPC), shared concerns and potential reforms in a conversation with Managed Healthcare Executive.
Read More
Exploring the Wide World of GLP-1s | AMCP Annual 2025
April 3rd 2025Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their effects on various other conditions, such as sleep apnea, substance use disorder and Alzheimer’s disease, according to panelists participating in a keynote session of the Academy of Managed Care Pharmacy annual meeting today in Houston.
Read More
